Trophos

Contact
trophos.com
+33491828282

Trophos SA

Parc scientifique de Luminy, Case 931
13288 Marseille
France
+33491828282
trophos.com
Contact
Profile News
Contact

About Trophos

Trophos is a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology.

Read more about Trophos
Facts about Trophos
  • Industry : Pharma

News about Trophos

Trophos

04-Mar-2013 | research and development

Trophos announces positive interim review in pivotal study of olesoxime in Spinal Muscular Atrophy

Trophos SA announced the completion of the interim analysis of the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal ...

Read news
Trophos

15-Aug-2012 | science

Trophos announces conclusion of MitoTarget Consortium, achieving advanced understanding of neurodegenerative diseases

Trophos SA announced the conclusion of the pan-European MitoTarget Project, the EU funded orphan disease project, with submission of the final report to ...

Read news
Trophos

19-Jun-2012 | people

Trophos appoints Christine Placet as chief executive officer

Trophos SA announced the appointment of Christine Placet as chief executive officer, effective immediately.Christine was previously CFO of Trophos since ...

Read news
Trophos

15-Dec-2011 | research and development

Trophos announces results of phase III study of olesoxime in Amyotrophic Lateral Sclerosis

Trophos SA announced the results from the phase III study of Trophos’ lead compound, olesoxime, in 512 patients with ALS. Olesoxime did not demonstrate a ...

Read news
Trophos

27-Sep-2011 | research and development

Trophos announces final patient completion of pivotal phase three efficacy study of olesoxime in Amyotrophic Lateral Sclerosis

Trophos SA announced that the last patient has now completed the major pivotal phase three efficacy study of olesoxime in Amyotrophic Lateral Sclerosis ( ...

Read news
Trophos

26-Aug-2011 | research and development

Trophos awarded key US patent covering use of novel cardioprotective compound, TRO40303

Patent protection granted until 2028

Read news
Trophos

28-Feb-2011 | research and development

Trophos successfully completes phase 1 study for novel cardioprotective compound, TRO40303

Phase 2 Proof-of-Concept study in acute myocardial infarction planned for second half 2011 with MitoCare EU consortium

Read news
Trophos

17-Dec-2010 | business & finance

Trophos to lead new MitoCare consortium awarded EUR 6 million by EU for POC study of novel cardioprotective compound, TRO40303

Program of translational research to study innovative approaches to reducing cardiac ischemia-reperfusion injury

Read news
Show more news about Trophos

Here you will find Trophos SA